Cancer antigen 125 concentrations in patients on chronic peritoneal dialysis: relationship with dialysis quality and membrane transport properties
Keywords:
peritoneal dialysis, cancer antigen 125, ACE inhibitors, erythropoietin, statinsAbstract
The aim of this study was to evaluate longitudinal changes in drained dialysate cancer antigen 125 (dCA-125) levels and to assess relationships between dCA-125 and dialysis quality, peritoneal membrane transport rates, dialysate glucose load, peritonitis and use of erythropoiesis stimulating agents (ESA), angiotensin-converting-enzyme inhibitors (ACEi) and statins in patients with end-stage renal failure during the first 6 months of peritoneal dialysis (PD) treatment. This prospective study included 20 patients (11 males and 9 females; mean age 62.90±12.69 years) who were followed-up during the first 6 months of PD using conventional low pH glucose-based dialysis fluids. The concentration of dCA-125 was measured in all patients, and the peritoneal equilibration test (PET), peritoneal dialysis treatment adequacy (Kt/V), normalized protein catabolic rate (nPCR), and total, peritoneal and residual clearances of urea and creatinine were calculated. Information on peritonitis occurrence, the use of ESA, ACEi and statins were collected. Data were analyzed by the Mann-Whitney test, Wilcoxon matched pairs test and Spearman’s rank correlation. The concentration of dCA-125 significantly decreased during the follow-up (p=0.016). After 6 months of PD treatment, the concentration of dCA-125 decreased significantly (p=0.016) in all patients. The decrease was present in all patients, but was statistically significant in patients on ACEi therapy (p=0.006) and in patients not using statins (p=0.005) or ESA (p=0.012). No correlation was found between dCA-125 and glucose load, but a statistically significant negative correlation between dCA-125 and the PET for creatinine was observed (p=0.013). These findings challenge the role of dCA-125 in predicting mesothelial cell integrity in PD patients.
https://doi.org/10.2298/ABS170324021J
Received: March 24, 2017; Revised: May 7, 2017; Accepted: May 9, 2017; Published onlione: June 12, 2017
How to cite this article: Jovanović NŽ, Trbojević-Stanković JB, Nešić DM, Obrenović RŽ, Boričić NI, Stojimirović BB. Cancer antigen 125 concentrations in patients on chronic peritoneal dialysis: Relationship with dialysis quality and membrane transport properties. Arch Biol Sci. 2018;70(1):13-20.
Downloads
References
Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001;276(29):27371-5.
Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 2002;98(5):737-40.
Duraisamy S, Ramasamy S, Kharbanda S, Kufe D. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene. 2006;373:28-34.
Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331-7.
Miralles C, Orea M, Espana P, Provencio M, Sancjez A, Cantos B, Cubedo R, Carcereny E, Bonilla F, Gea T. ancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003;10(2):150-4.
Ercan S, Kaymaz O, Yucel N, Orcun A. Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study. Arch Gynecol Obstet. 2012;285(3):579-84.
Mitić N, Janković M. Activity profile of the CA 125 antigen towards human red blood cells. Arch Biol Sci. 2010;62(2):271-80.
Hung C-L, Hung T-C, Lai Y-H, Lu C-S, Wu Y-J, Yeh H-I. Beyond malignancy: the role of carbohydrate antigen 125 in heart failure. Biomark Res.2013:1:25.
Zeimet AG, Marth C, Offner FA, Obrist P, Uhl_Steidl M, Feichtinger H. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996;62:384-89.
Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int. 2001;21(6):560-7.
Fusshöller A, Grabensee B, Plum J. Effluent CA 125 concentration in chronic peritoneal dialysis patients: influence of PD duration, peritoneal transport and PD regimen. Kidney Blood Press Res. 2003;26(2):118-22.
Breborowicz A, Breborowicz M, Pyda M, Połubinska A, Oreopoulos D. Limitations of CA125 as an index of peritoneal mesothelial cell mass. Nephron Clin Pract. 2005;100:c46-c51.
Cheema H, Bargman JM. Cancer antigen 125 as a biomerker in peritoneal dialysis mesothelial cell health or death? Perit Dial Int. 2013;33(4):349-52.
Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int. 1985;28:526-34.
Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr. 1980;33:27-39.
Dubois D, Dubois EF. A formula to estimate the approximative surface area if height and weight are known. Arch Intern Med. 1960;17:863-71.
Mandolfo S, Zucchi A, Cavalieri D, Oro L, Corradi B, Imbasciati E. Protein nitrogen appearance in CAPD patients: what is the best formula. Nephrol Dial Transplant. 1996;11:1592-6.
Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP. Peritoneal equilibration test. Perit Dial Bull. 1987;7:138-47.
Perez BH, Gipson IK. Focus on Molecules: human mucin MUC16. Exp Eye Res. 2008; 87 (5): 400-1.
Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998;13(4):179-87.
Topley N, Michael D, Chalice T. Ca125: Holy grail or poisoned chalice. Nephron 2005; 100: c52-4.
Visser CE, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beelen RH, Krediet RT. Ca125: a bulk marker for mesothelial cell mass in stable peritoneal dialysis patients. Nephrol Dial Transplant. 1995;10:64-9.
Trbojević-Stanković J, Obradović M, Cemerikić-Martinović V, Trpinac D, Lausević Z, Stojimirović B. Immunohistochemical study of pathological alterations of peritoneum in patients with terminal renal insufficiency and on peritoneal dialysis. Vojnosanit Pregl. 2011;68(7):556-60.
Pannekeet, Marja M. Ho-Dac; Hiralall JK, Struijk DG. Krediet RT. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int. 1997;51(3):888-93.
Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J and the Euro Balance Trial Group. The euro-balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 2004;66:408-18.
Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate /lactate-buffered peritoneal dialysis fluid in APD: a prospective randomized study. Nephrol Dial Transplant. 2004;19:2101-6.
Rodrigues A, Martins S, Santos MJ: Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor and interleukin-6. Relationship with peritoneal transport. Adv Perit Dial. 2004;20:8-12.
le Poole CY, Welten AGA, Piet M. ter Wee, Paauw NIJ., Djorai AN, Valentijn RM, Beelen RHJ, van den Born J, van Ittersum FJ. A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation. Perit Dial Int. 2012;32(3):305-15.
Passadakis P, Panagoutsos S, Thodis E, Tsivara I, Sopassi F, Kartali S, Vargemezis V. Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients. Adv Perit Dial. 1999;15:40-4.
Barreto DL, Coester AM, Noordzij M, Smit W, Struijk DG, Rogers S, de Waart DR, Krediet RT. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients. Nephrol Dial Transplant. 2011;26:3739-44.
Panorchan K, Davenport A. Diagnostic and prognostic role of peritoneal Ca 125 in peritoneal dialysis patients presenting with acute peritonitis. BMC Nephrol. 2014;15:149.
Jiménez C, Díaz C, Selgas R, Auxiliadora Bajo M, del Peso G, Sánchez-Tomero JA, Gonzalez-Gancedo P. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome. Adv Perit Dial. 1999;15:36-9.
Barreto DL, Krediet RT. Current status and practical use of effluent biomarkers in peritoneal dialysis patients. Am J Kidney Dis. 2013;62(4):823-33.
Duman S, Günal AI, Sen S, Asçi G, Ozkahya M, Terzioglu E, Akçiçek F, Atabay G. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int. 2001;21:219-24.
Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs. 2005;28:156-63.
Özlem Tir, YAki Celalettin Usalan. The effect of atorvastatin therapy in CAPD Patients on inflammatory markers (CRP) and dialysate IL-6 and Ca-125 Level. Turk Neph Dial Transpl. 2011;20(3):284-9.
Yelken B, Gorgulu N, Gursu M, Yazici H, Caliskan Y, Telci A, Ozturk S, Kazancioglu R, Ecder T, Bozfakioglu S. Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients. Adv Perit Dial. 2014;30:305-10.
Candan C1, Turhan P, Sever L, Civilibal M, Canpolat N, Caliskan S, Kasapcopur O, Arisoy N. Dialysate CA125 levels after 5 years on continuous peritoneal dialysis. Pediatr Nephrol. 2011;26(5):783-8.
Han D-S, Lee HY. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial. Perit Dial Int. 2008;28:174-82.
Downloads
Published
How to Cite
Issue
Section
License
Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
